Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis. Adam Feuerstein, senior columnist at TheStreet, breaks down the study results of the TRAFFIC and TRANSPORT phase III studies, which when pooled together, resulted in a 3.3% improvement in cystic fibrosis patients' lung function on an absolute basis. Feuerstein reveals whether the results are clinically meaningful and how significant they're likely to be regarded by industry watchers. With the stock soaring pre-market on the news, Feuerstein also explains what the results should mean to shares of Vertex going forward.
Stocks in this video: